Poor asthma control during pregnancy emerges as a critical maternal health factor that extends far beyond respiratory symptoms, potentially affecting both mother and child in ways that challenge traditional risk assessments. The condition affects one in eight pregnant women globally, yet its broader implications for pregnancy outcomes remain underappreciated in routine obstetric care.
Severe or inadequately managed asthma significantly elevates risks for preeclampsia, gestational diabetes, and fetal growth restriction, while also increasing likelihood of preterm delivery. Newborns face heightened risks of breathing difficulties, intensive care requirements, seizures, and blood sugar instabilities. The review emphasizes that contrary to common assumptions, pregnancy's physiological changes don't inherently worsen asthma severity—any decline in lung function ratios should trigger immediate clinical investigation.
This analysis reveals a paradigm shift toward personalized, biomarker-guided asthma management that could revolutionize pregnancy care. Modern biologic therapies and trait-based treatment approaches, previously reserved for non-pregnant populations, show promise for expectant mothers with severe disease. The findings challenge the traditional conservative approach to asthma treatment during pregnancy, suggesting that aggressive disease control may prevent cascading complications.
The research underscores a critical gap in integrated care—asthma management during pregnancy requires coordination between respiratory specialists and obstetric teams. For the millions of women with asthma planning pregnancies, this evidence supports proactive disease optimization before conception and intensive monitoring throughout gestation, potentially preventing serious maternal and neonatal complications through contemporary therapeutic strategies.